8 active trials 3 recruiting 3 Phase 3 5 disease areas 2 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Trial sites reduced: 199 → 191 locations
Also in this update: Primary completion date changed from estimate of Aug 2026 to May 22, 2026
Karyopharm Therapeutics IncPhase 3 NCT05611931 Registry history of NCT05611931 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1/2 | 1 | |
| Phase 2 | 4 | |
| Phase 2/3 | 1 | |
| Phase 3 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Myelofibrosis | Active, Not Recruiting | 2026-10-01 |
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53… | Endometrial Cancer | Active, Not Recruiting | 2026-09-30 |
| Phase 2/3 | ||||
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor… | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Active, Not Recruiting | 2026-10-02 |
| Phase 2 | ||||
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple… | Multiple Myeloma, Refractory | Recruiting | 2026-10-01 |
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and… | Myelofibrosis | Recruiting | 2026-02-12 |
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma… | Diffuse Large B-cell Lymphoma | Active, Not Recruiting | 2026-10-01 |
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With… | Myelofibrosis | Active, Not Recruiting | 2026-07-02 |
| Phase 1/2 | ||||
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Multiple Myeloma | Recruiting | 2026-07-15 |
Myelofibrosis (3) · DLBCL (2) · Multiple Myeloma (2) · Non-Hodgkin Lymphoma (2) · Endometrial Cancer (1)